Quest Diagnostics Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Syros' Blood Cancer Drugs Land Orphan Designation From FDA Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)

Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics Inc. said Thursday its fourth-quarter net income fell to $390 million or $3.12 a share, from $579 million or $4.21 a share in the year-ago quarter. The blood testing company''s adjusted net income dropped to $3.33 a share from $4.48 a share. Revenue fell 8.6% to $2.74 billion. Analysts expected Quest Diagnostics to earn $3.22 a share on revenue of $2.68 billion, according to a survey by FactSet. Looking ahead, Quest Diagnostics forecasts 2022 earnings of $7.63 to $8.33 a share and adjusted profit of $8.65 to $9.35 a share, against the Wall Street consensus estimate of $8.75 a share. Separately, Quest Diagnostics said it boosted its quarterly dividend by 6.5% to 66 cents a share, starting on April 20 to shareholders of record as of April 6. Shares of Quest Diagnostics have fallen 21.4% so far in 2022, compared to a dip of 3.7% by the S&P 500. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

SECAUCUS, N.J. , Feb. 3, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX ), the nation''s leading provider of diagnostic information services, today announced that its Board of Directors, as part of its ongoing leadership succession planning, has appointed James E. Davis , Executive Vice President, General Diagnostics, to be its next Chief Executive Officer, effective November 1, 2022 . At that time, Mr. Davis will succeed Steve Rusckowski , who will have served as CEO for more than a decade. Mr. Rusckowski, 64, currently Chairman, CEO and President, will continue to serve on the Quest Board of Directors as Executive Chairman through March 2023. "Today, Quest is the clear leader in diagnostic information services, positioned for continued execution of its ambitious growth plans under a new CEO in Jim Davis , who has been instrumental in accelerating growth and driving the company''s operational excellence program for eight years," said Tim Ring , Quest''s Lead Independent Director. "Jim is uniquely qualified to lead Quest in its next phase of growth, and this gradual and comprehensive transition process will ensure continuity for the company''s strong market momentum." Mr.

Quest Diagnostics Incorporated (NYSE:DGX) declares $0.66/share quarterly dividend, 6.5% increase from prior dividend of $0.62.Forward yield 1.94%Payable April 20; for shareholders of record

Quest Diagnostics press release (DGX): Q4 Non-GAAP EPS of $3.33 beats by $0.14.Revenue of $2.74B (-8.7% Y/Y) beats by $80M.Full year 2022 reported diluted EPS expected to be

Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.

Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.60% and 0.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Quest Diagnostics Inc. DGX, +0.50% said Thursday its fourth-quarter net income fell to $390 million or $3.12 a share, from $579 million or $4.21 a share in the year-ago quarter. The blood testing comp

Quest Diagnostics (NYSE:DGX) is scheduled to announce Q4 earnings results on Thursday, February 3rd, before market open.The consensus EPS Estimate is $3.18 (-29.0% Y/Y) and the

Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09 in the year-ago quarter. At

Quest Diagnostics (DGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Encompass Health (EHC) delivered earnings and revenue surprises of -8.49% and 1.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

The risk of developing severe COVID-19 for people who are fully vaccinated and have received a booster dose is close to zero, according to the latest data from the Centers for Disease Control and Prev